Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MGAT5_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MGAT5_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MGAT5_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MGAT5_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MGAT5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/MGAT5_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MGAT5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MGAT5_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MGAT5_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00105636 | Stomach | GC | negative regulation of phosphorus metabolic process | 46/1159 | 442/18723 | 3.90e-04 | 5.97e-03 | 46 |
GO:00109216 | Stomach | GC | regulation of phosphatase activity | 13/1159 | 84/18723 | 1.89e-03 | 1.94e-02 | 13 |
GO:00436665 | Stomach | GC | regulation of phosphoprotein phosphatase activity | 10/1159 | 58/18723 | 2.73e-03 | 2.52e-02 | 10 |
GO:00353046 | Stomach | GC | regulation of protein dephosphorylation | 13/1159 | 90/18723 | 3.53e-03 | 3.02e-02 | 13 |
GO:00353083 | Stomach | GC | negative regulation of protein dephosphorylation | 7/1159 | 34/18723 | 4.21e-03 | 3.49e-02 | 7 |
GO:0032515 | Stomach | GC | negative regulation of phosphoprotein phosphatase activity | 6/1159 | 26/18723 | 4.38e-03 | 3.60e-02 | 6 |
GO:00353036 | Stomach | GC | regulation of dephosphorylation | 16/1159 | 128/18723 | 5.64e-03 | 4.34e-02 | 16 |
GO:001603211 | Stomach | CAG with IM | viral process | 55/1050 | 415/18723 | 2.54e-09 | 2.88e-07 | 55 |
GO:005134611 | Stomach | CAG with IM | negative regulation of hydrolase activity | 44/1050 | 379/18723 | 3.90e-06 | 1.52e-04 | 44 |
GO:004593611 | Stomach | CAG with IM | negative regulation of phosphate metabolic process | 40/1050 | 441/18723 | 1.91e-03 | 2.02e-02 | 40 |
GO:001056311 | Stomach | CAG with IM | negative regulation of phosphorus metabolic process | 40/1050 | 442/18723 | 1.99e-03 | 2.09e-02 | 40 |
GO:003530411 | Stomach | CAG with IM | regulation of protein dephosphorylation | 12/1050 | 90/18723 | 4.37e-03 | 3.69e-02 | 12 |
GO:004366611 | Stomach | CAG with IM | regulation of phosphoprotein phosphatase activity | 9/1050 | 58/18723 | 4.73e-03 | 3.86e-02 | 9 |
GO:001603221 | Stomach | CSG | viral process | 53/1034 | 415/18723 | 1.07e-08 | 9.41e-07 | 53 |
GO:005134621 | Stomach | CSG | negative regulation of hydrolase activity | 44/1034 | 379/18723 | 2.62e-06 | 1.16e-04 | 44 |
GO:004593621 | Stomach | CSG | negative regulation of phosphate metabolic process | 40/1034 | 441/18723 | 1.45e-03 | 1.67e-02 | 40 |
GO:001056321 | Stomach | CSG | negative regulation of phosphorus metabolic process | 40/1034 | 442/18723 | 1.51e-03 | 1.71e-02 | 40 |
GO:003530421 | Stomach | CSG | regulation of protein dephosphorylation | 12/1034 | 90/18723 | 3.87e-03 | 3.40e-02 | 12 |
GO:004366621 | Stomach | CSG | regulation of phosphoprotein phosphatase activity | 9/1034 | 58/18723 | 4.28e-03 | 3.68e-02 | 9 |
GO:001092111 | Stomach | CSG | regulation of phosphatase activity | 11/1034 | 84/18723 | 6.37e-03 | 4.92e-02 | 11 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MGAT5 | SNV | Missense_Mutation | rs375709714 | c.700N>A | p.Glu234Lys | p.E234K | Q09328 | protein_coding | tolerated(0.2) | probably_damaging(0.991) | TCGA-3C-AAAU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | zoladex | SD |
MGAT5 | SNV | Missense_Mutation | novel | c.133A>C | p.Met45Leu | p.M45L | Q09328 | protein_coding | tolerated(0.25) | benign(0.001) | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
MGAT5 | SNV | Missense_Mutation | rs548835362 | c.110N>A | p.Arg37Gln | p.R37Q | Q09328 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MGAT5 | SNV | Missense_Mutation | | c.1080N>C | p.Lys360Asn | p.K360N | Q09328 | protein_coding | tolerated(0.06) | probably_damaging(0.994) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MGAT5 | SNV | Missense_Mutation | rs755158785 | c.742G>A | p.Ala248Thr | p.A248T | Q09328 | protein_coding | tolerated(0.4) | benign(0.003) | TCGA-AC-A62V-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Targeted Molecular therapy | denosumab | PD |
MGAT5 | SNV | Missense_Mutation | novel | c.1304N>T | p.Ser435Ile | p.S435I | Q09328 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-D8-A27R-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin+cyclophosphamide | SD |
MGAT5 | SNV | Missense_Mutation | rs376303600 | c.1181C>T | p.Ser394Leu | p.S394L | Q09328 | protein_coding | tolerated(0.86) | benign(0.007) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
MGAT5 | insertion | Frame_Shift_Ins | novel | c.135_136insTTAACACACGCAGACGCACA | p.Arg47ThrfsTer38 | p.R47Tfs*38 | Q09328 | protein_coding | | | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
MGAT5 | insertion | In_Frame_Ins | novel | c.514_515insTTTTCATTGCTGAGGTTCAGTGTGGTCAAG | p.Cys172delinsPhePheIleAlaGluValGlnCysGlyGlnGly | p.C172delinsFFIAEVQCGQG | Q09328 | protein_coding | | | TCGA-A8-A0A9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
MGAT5 | insertion | In_Frame_Ins | novel | c.1901_1902insTGGAAG | p.Pro634_Leu635insGlySer | p.P634_L635insGS | Q09328 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |